"Medical Journeys" chart a path each step of the way for physicians and patients and provide continual resources and support, ...

About half of people with "chronic spontaneous urticaria," or CSU, the most common type of chronic hives, experience what ...

Diagnosing CSU can be difficult for a few main reasons, including the following: CSU is often misdiagnosed because hives are ...

MCLEAN, VA / ACCESSWIRE / December 10, 2024 / Dr. Amir Bajoghli and his colleagues have recently published an insightful case ...

A new approach to treat rosacea and other inflammatory skin conditions could be on the horizon, according to a University of Pittsburgh study published today in Science Translational Medicine.

A new approach to treat rosacea and other inflammatory skin conditions could be on the horizon, according to a University of ...

Celltrion today announced that Health Canada has approved Omlyclo™, a biosimilar referencing Xolair®. Omlyclo™ is approved ...

Galderma Receives U.S. FDA Approval for Nemluvio® (Nemolizumab) for Patients with Moderate-to-Severe Atopic Dermatitis ...

It's still early science -- studies in mice and in human cells -- but researchers are on the trail of an effective n ...

Ligelizumab is a monoclonal antibody commercialized by Novartis, with a leading Phase III program in Food Allergy.